Catalyst Wire Dossier Catalyst Wire Dossier

BCMA/CD3 bispecific antibody therapy

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for BCMA/CD3 bispecific antibody therapy, covering 2025-08-11 to 2025-09-08. Get the full timeline:

Most recent: Clinical Trial Update: Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration [Phase 2]

See pricing